Susan Band Horwitz | |
---|---|
Born | 1937 Cambridge, Massachusetts |
Nationality | American |
Alma mater | Bryn Mawr College, Brandeis University |
Known for | Anti-tumor drugs |
Scientific career | |
Fields | Biochemistry |
Institutions | Tufts University Medical School, Emory University Medical School, Albert Einstein College of Medicine |
Doctoral advisor | Nathan O. Kaplan |
Susan Band Horwitz is an American biochemist and professor at the Albert Einstein College of Medicine[1][2] where she holds the Falkenstein chair in Cancer Research as well as co-chair of the department of Molecular Pharmacology.
Horwitz is a pioneer in dissecting the mechanisms of action of chemotherapeutic drugs including camptothecin, epipodophyllotoxins, and bleomycin, and taxol. Horwitz's work on taxol in particular has brought her international recognition. Horwitz discovered that taxol binds to microtubules, resulting in arrest of the cell cycle in metaphase.[1] Her work paved the way to using taxol and other microtubule binding agents as chemotherapeutics. Taxol remains widely used today, as a means to treat ovarian, breast, and lung cancer.[3] However, since taxol is in short supply, Horwitz is directing studies in her lab to identify similar therapies in natural products.